Experiments were performed with BALB/c mice to elucidate the roles of humoral and cell-mediated immune responses in the acquisition of protective immunity to Brucella ovis and to compare infection immunity with immunity developed through vaccination with a hot saline extract (HS) of B. ovis. Mice convalescing from a primary infection with B. ovis displayed a high level of resistance to reinfection, as evidenced by splenic bacterial counts decreased over 10,000-fold from control groups at 2 weeks after challenge. Passive transfer assays revealed that protection was mediated by both T lymphocytes and antibodies but that antibodies had a substantially greater role on the basis of log units of protection that were transferred. Antibodies specific for HS proteins in sera from convalescent mice were predominantly of the immunoglobulin G 2a and 3 isotypes. Vaccination with HS conferred good protection against B. ovis, but protection was greatly enhanced by the incorporation of QS-21 or other adjuvants. Protection provided by the HS vaccine resulted largely from immune responses to its protein moieties. A critical evaluation of the protective efficacy of the rough lipopolysaccharide component of HS was precluded by its poor immunogenicity in BALB/c mice. HS-QS-21 afforded protection against challenge infection with B. ovis as good as that which developed after a primary infection and as good as or better than that provided by attenuated Brucella melitensis vaccine strain Rev 1. Passive transfer experiments confirmed that the magnitudes of both humoral and cell-mediated forms of protective immunity were equivalent in mice vaccinated with HS-QS-21 and those recovering from a primary infection. Protective immunity to B. ovis in mice therefore resembled that to Brucella abortus, except that the relative roles of humoral and cell-mediated immunity, rather than being equivalent, were shifted toward a greater role for antibodies.
HS antigens, particularly the surface-exposed group 3 protein, might induce a protective immune response to B. ovis. In fact, we have preliminary evidence that HS incorporated with an adjuvant induced significant levels of protection in rams against B. ovis (8) .
Despite the recognized economic importance of ovine brucellosis and ongoing efforts to develop alternative vaccines to Rev 1, nothing is known about the nature of protective immunity to this disease. This stands in marked contrast to Brucella abortus, for which the mouse model has been extensively employed in recent years to study a variety of hostparasite interactions and the development of protective immunity (5) . The objectives of the present work were, first, to use the mouse model in order to define the roles of humoral and cell-mediated immune responses in the elimination of B. ovis in a primary infection. We then wished to evaluate the protective qualities of the HS vaccine and to compare the magnitude of protective immunity acquired through vaccination with that which developed during a primary infection. Our selection of a vaccine for a future field trial with rams would depend upon its ability to induce protection in both humoral and cell-mediated compartments at least as good as that which followed recovery from disease.
MATERIALS AND METHODS
Mice. Female BALB/cByJ mice were purchased from the Jackson Laboratory (Bar Harbor, Maine) 1 week before use. Mice to be used in vaccination experiments were shipped at 5 weeks of age, while animals scheduled for passive transfer experiments were shipped at 9 weeks of age.
Bacterial strains. B. ovis PA was obtained from J. M. Verger (Station de Pathologie Infectieuse et Immunit6, Institut National de la Recherche Agronomique, Nouzilly, France). B. melitensis 16M and Rev I were supplied by G. G. Schurig (Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg, Va.). B. ovis PA and B. melitensis 16M were used as challenge strains after two serial passages in BALB/c mice and isolation in pure culture from spleens. Stock cultures were prepared from 48-h growth on Schaedler blood agar plates and were stored at -70°C in Albimi broth (Difco Laboratories, Detroit, Mich.). For infection, contents of freshly thawed vials were diluted with sterile phosphate-buffered saline (PBS) to the desired concentration. Exact numbers of cells were established retrospectively by viable counts (36) .
Antigens for vaccines and immunoassays. HS from B. ovis REO 198 was obtained as described previously (17, 41) by suspending live cells in physiological saline (10 g of packed cells per 100 ml) and heating the suspensions in flowing steam for 15 min. After centrifugation at 12,000 x g for 15 min, the supernatant was dialyzed for 2 days at 4°C against several changes of distilled deionized water. The dialyzed material was centrifuged for 5 h at 100,000 x g, and the pellet (HS) was suspended in distilled deionized water and lyophilized. The product produced a typical profile by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, with group 3 outer membrane proteins by far the dominant component (data not shown). HS proteins (HS-PCP) were purified by extraction of 2 mg of HS with 7 ml of a mixture of petroleum ether, chloroform, and phenol (PCP) (23) for 1 min at 16,000 rpm in a homogenizer (Sorvall Omnimixer; Dupont Co., Wilmington, Del.). After centrifugation at 12,000 x g, the sediment (HS-PCP) was washed once and then suspended in distilled deionized water and lyophilized (41) .
R-LPS was obtained from HS by elimination of proteins with the PCP protocol followed by precipitation of R-LPS from the phenol phase with water (41) . The final product had a protein content of 0.6% (dry weight) and a 2-keto-3-deoxyoctulosonic acid content of 2.8% (dry weight), which represented an LPS content of approximately 51% (37 (3) . After I h, recipients were challenged i.v. with 5 x 103 CFU of B. ovis PA, and 2 weeks thereafter, mice were killed and spleen counts were made.
Control groups received PBS since it had been established that there were no differences in splenic numbers of B. ovis between groups that were injected with 0.1 ml of PBS and those that received either 0.1 ml of normal mouse serum or 3 x 1() normal T cells prior to inoculation with B. ovis (difference in mean counts, <0.1 log," unit). Recipient groups receiving T cells were bled prior to sacrifice.
KELA. Antibodies against HS and R-LPS were measured in an indirect, computer-assisted kinetics-based enzyme-linked assay (KELA), as described previously (53) , with a goat anti-mouse IgM, IgG, and IgA horseradish peroxidase conjugate (Cappel, Organon Teknika, Durham, N.C.). In selected tests, goat anti-mouse horseradish peroxidase conjugates specific for individual isotypes (IgM, IgGl, IgG2a, IgG2b, and IgG3) (Southern Biotechnology Associates, Birmingham, Ala.)
were used under the same conditions. The rate of the reaction between substrate solution and enzyme, expressed as slope, is directly proportional to the amount of antibody in the sample (51) and was determined from linear regression analysis of time versus absorbance. Data from assays performed on sep- (48) .
RESULTS
Growth patterns of B. ovis PA and B. melitensis 16M. After two passages in mice, B. ovis PA grew readily in the spleen. Low inoculum numbers became established and increased by approximately 5 logs during the first 2 1/2 weeks p.i., followed by a gradual decline (Fig. la) . The plateau at 2 weeks p.i. (Fig.  la) was not reproduced in subsequent experiments in which counts at 2 weeks p.i. were at least 1 log higher (Table 1 and  see Tables 4 to 6 ). The challenge dose selected for most experiments was 5 x 103 CFU, with an interval of 2 weeks between challenge and sacrifice. In some experiments, a 10-fold-higher challenge dose was used, resulting in splenic cell numbers exceeding 108 by 2 weeks p.i. (see Tables 3 and 5) .
Twice-passaged B. melitensis 16M produced a growth curve over the first 3 weeks p.i. resembling that of virulent B. abortus 2308 (36) . Numbers increased during the first 1 1/2 weeks p.i., peaked at levels much lower than those of B. ovis PA, and then plateaued (Fig. lb) . A challenge dose of 5 x 104 CFU of strain 16M was used with a challenge-to-sacrifice interval of 2 weeks.
Rev 1 replicated actively in the spleens of BALB/c mice during the first 2 weeks p.i. (data not shown), in accord with prior observations (10) .
None of these strains produced clinical signs of disease. Infection immunity. Mice convalescent from infection with B. ovis PA were highly resistant to reinfection with the homologous strain. In separate experiments, groups of mice challenged with B. ovis PA (5 x 103 CFU) 10 1/2 or 13 weeks after an initial infection exhibited 4.57 and 5.39 log units of protection (P < 0.001), respectively, compared with control groups of naive mice.
Immunity through vaccination with HS. Mice were vaccinated with graded quantities of HS, with and without QS-21. High levels of protection were obtained with 20 or 2 ,ug of HS incorporated with QS-21, whereas only the higher dose of antigen was protective in the absence of adjuvant (Table 1) . A vaccine composed of 20 p.g of HS plus QS-21 was selected for subsequent studies. A clear association existed among the groups between the concentration of circulating HS-specific antibodies at the time of challenge and the level of protection obtained ( Table 1 ). The presence of QS-21 resulted in large and highly significant (P < 0.01 to P < 0.001) increases in antibodies of the IgGl, IgG2a, and IgG2b isotypes ( Table 2) . A similar distribution of isotypes occurred in three other serum pools of mice that had been vaccinated with HS-QS-21, except that the level of IgG3 antibodies was substantially higher (Table 2) . Whereas IgG2a and IgG2b antibodies predominated in mice vaccinated with HS-QS-21, infection with B. ovis induced predominantly IgG2a and IgG3 antibodies, with IgGl at the lowest level (Table 2) .
In another experiment with a 10-fold-higher challenge dose, inclusion of QS-21 with HS resulted in significantly higher antibody levels (P < 0.001) and significantly better protection than that provided by HS alone (P < 0.01) or Rev 1 (P < 0.01) ( Table 3) . Incorporation of adjuvant L-121 or Montanide 888, with or without tMDP, also induced high concentrations of "Three serum pools used in passive transfer assays. Mice were bled 1 week after the second vaccination. Pools were composed of serum samples from 10 to 20 donor mice.
e Three serum pools used in passive transfer assays. Mice were bled at 9, 10, and 13 weeks p.i., respectively. Each pool was composed of serum samples from 10 donor mice.
antibodies and high levels of protection ( Table 3 ) that did not differ significantly from the values recorded for QS-21.
Both HS-QS-21 and live Rev 1 vaccines produced significant protection against B. ovis (P < 0.001 and P < 0.01, respectively) (Table 4 ), but protection provided by HS-QS-21 was significantly greater (P < 0.01). In contrast, the HS-QS-21 vaccine failed to provide any protection against B. melitensis 16M, while Rev 1 was highly protective (Table 4) . A repetition of this experiment produced the same results, except that HS-QS-21 and Rev 1 gave equivalent protection against B. ovis (data not shown). In two further comparisons, protection against B. ovis PA provided by vaccination with HS-QS-21 was equivalent to, or significantly greater than, that which resulted from vaccination with Rev-1 (data not shown).
Vaccination with HS-PCP, the purified protein fraction of HS, provided protection against B. ovis as good as that with HS when a high challenge dose (5.8 x 104 CFU) was used, whereas purified R-LPS was completely ineffective ( Table 5 ). The same results were obtained with HS and HS-PCP in two repetitions of this experiment with a 10-fold-lower challenge dose. With the lower challenge dose, R-LPS was also protective, although at levels 10-fold or more below those of HS-PCP (data not shown). Mice vaccinated with R-LPS produced extremely low antibody responses to that antigen, and in mice vaccinated with intact HS, the R-LPS-specific antibodies represented a negligibly small proportion of the total antibody response (Table 5 [other data not shown]). The immunogenicity of R-LPS could not be improved by coupling it to bovine serum albumin (BSA) (data not shown).
Passive transfer of immunity. T cells from spleens of convalescent donors ( 5) , and the low number of residual B cells that were transferred (0.9%) precluded a significant contribution from antibodies. Antiserum pools from all three donor groups provided significant levels of protection (P < 0.001 to P < 0.05) that were much higher in log units than protection given by the corresponding pools of T cells (Table 6 ). In another experiment with the same antiserum pools, results were very similar (data not shown), except that protection with the group 4 serum (HS, s.c. vaccination) was higher and more consistent (3.31 log units, P < 0.01). In a separate experiment, antisera from convalescent or vaccinated mice again provided high levels of protection (ranging from 2.36 [P < 0.01] to 4.31 [P < 0.001] log units) that exceeded the protection obtained from the corresponding pools of T cells by 1.39 to 3.39 log units (data not shown). 
DISCUSSION
The data presented here demonstrate that the BALB/c mouse, recognized as a useful model for brucellosis caused by B. abortus (5), may also be used to advantage for studying B. ovis. Thus, B. ovis replicated readily in the spleen (Fig. la) and liver (29a) to produce a chronic and asymptomatic infection which was overcome through a potent immune response (Table 6 ). In a recent study with B. ovis PA in outbred CD1 mice, bacterial replication was limited or failed to occur (29) . This was probably due in part to greater inherent resistance of the CD1 strain, which was also more resistant than BALB/c mice to B. abortus (52) . In addition, it is likely that the twice-passaged strain used in this study was more virulent.
Although the status of B. ovis as a facultative intracellular bacterium capable of survival in macrophages has yet to be established, passive transfer experiments now demonstrate that, in mice, protection is partially attributable to cell-mediated immunity (Table 6 ). The identity of the protective cell type or types is not yet known. The induction by B. ovis of a dominant CD4+, THi population known to be protective against several protozoan agents (45) was suggested by the predominance in infected mice of IgG2a and IgG3 antibodies, coupled with minimal IgGl responses (Table 3 ). B. abortus, which stimulates a polyclonal THI response (22, 49) , induces primarily IgG2a and IgG3 antibodies specific for covalently bound haptens (46) or B. abortus outer membrane proteins (19) . Recent evidence (47) indicates that gamma interferon exerts control over IgG3 as well as IgG2a synthesis. Since there is now strong support for a protective function of natural killer cells (18) and -y5 T cells (27, 43) in murine listeriosis, the involvement of one or both of these cell types in protection against B. ovis is also possible. However, excellent protection was transferred by lymph node lymphocytes in which CD4+ and CD8+ cells accounted for the total cell population ( Table   6 ), indicating that these cell populations had an important role in providing cell-mediated immunity to B. ovis.
Whereas immune T cells were largely absent from the spleens of HS-vaccinated mice prior to challenge infection, T cells from the popliteal nodes of mice vaccinated in the hind footpads provided the highest level of protection of any T-cell preparation tested (Table 6 and other data). We believe that the paucity of immune T cells in the spleens of HS-vaccinated mice prior to challenge infection occurred because, during the first weeks after the two vaccinations, these cells would have localized predominantly in the inflamed draining lymph nodes, which would have contained substantial quantities of antigen absorbed from the injection sites. In like fashion, immune T cells would have localized in the spleens of mice undergoing active infection in that organ, including the spleens of the HS-vaccinated mice following i.v. challenge infection.
The remarkably high levels of protection obtained with antibodies in passive transfer assays (Table 6 ), orders of magnitude higher than those achieved against B. abortus (3, 4, 20) , may have several explanations. In B. abortus infection, for example, passive protection by IgG antibodies against attenuated vaccine strain 19, which is readily killed within macrophages when opsonized by IgG antibodies, is consistently 1 log unit greater than that against virulent strain 2308, which is more resistant to killing when comparably opsonized (20, 30) . The protective functions of antibodies against B. ovis could have included opsonization with enhancement of intracellular killing or mediation of extracellular killing by complement or through antibody-dependent cellular cytotoxicity by natural killer or other effector cells.
Protection transferred by three antiserum pools from convalescent mice ranged from 2.36 to 5.25 log units, while that from HS-vaccinated donors ranged from 2.68 to 5.10 log units. It is unclear why some antiserum pools conferred higher levels d ***P < 0.01, ***P < 0.001, and *P < 0.05 compared with PBS control group. t, not significant. e B. ovis was not detected in any of the spleens, so a logl0 value of 2.12 was assigned to the group according to the previous convention (36) .
of protection than others. Such differences were not associated with total antibody concentrations determined by KELA (Table 6). In fact, antiserum pools from convalescent mice were overall as protective as those from vaccinated groups, despite lower levels of antibodies of all isotypes (Tables 2 and 6 ). Even though there was no difference in the recognition of antigens on methanol-killed whole B. ovis cells by convalescent phase sera and sera induced by the heat-treated HS antigens as judged by KELA (28a), some differences in the fine specificity of antibodies that could have affected protection may have existed between them. The importance of the protein constituents of HS in accounting for protective immunity was illustrated by the induction of equivalent protection by purified proteins (HS-PCP) and intact HS (Table 5) . Purified R-LPS also induced low levels of protection against a lower challenge dose, but the poor immunogenicity of R-LPS in BALB/c mice (Table 5) precludes an unqualified judgment of its protective efficacy. Although outer membrane protein antigens of B. ovis and B. melitensis are antigenically related (24, 41, 44) , HS-specific antibodies would probably not have been protective against B. melitensis with its surface-exposed 0 polysaccharide, and crossprotective cell-mediated immune responses were apparently not induced by HS (Table 4) .
The combination of HS and QS-21 fulfills our criteria for selection of an appropriate vaccine for a field trial with rams. Aside from its potency in inducing antibodies (Tables 1 to 3 and 5) that were demonstrated to be protective (Table 6) , HS-QS-21 evoked a protective cell-mediated immune response as good as that obtained from the T cells of convalescent mice (Table 6 ). It remains to be seen whether the protective T cells induced by vaccination with HS-QS-21 and through primary infection with B. ovis are distributed into the same subsets. However, the ability of QS-21 to stimulate the formation of a major histocompatibility complex class I-restricted CD8 T-cell response to a simple protein antigen has already been established (38) and represents an essential attribute of an adjuvant for subcellular vaccines against intracellular parasites. An additional important advantage of QS-21 lies in the extreme simplicity of vaccine preparation and administration, coupled with the absence of oils and emulsifying agents from the injected product.
